Merck Seeks 25% of Sales From Emerging Markets by 2013

Merck & Co., the world’s second-largest drugmaker, aims to generate a quarter of annual revenue from emerging markets by 2013 as surging economic growth spurs disease diagnosis and demand for treatments, an executive said.

Merck gets 18 percent of its sales from emerging markets at present, Ramesh Subrahmanian, the drugmaker’s president of Asia-Pacific, said in an interview in Singapore today.